KRAS TCR-Transduced PBL(NIH)

N/A

Report date: 2025/09/12 20:01:19

Base Information

Drug NameKRAS TCR-Transduced PBL(NIH)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derived

Mechanisms of ActionT lymphocyte replacementsV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog modulators

TargetsGTPase KRas

Therapy Area/IndicationsPancreatic NeoplasmsDuodenal NeoplasmsColorectal Neoplasms +[8]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Cancer Institute

Active IndicationsN/A

Inactive IndicationsPancreatic NeoplasmsDuodenal NeoplasmsColorectal Neoplasms +[8]

Other Information

ATC CodeN/A